SCHEMBL24256967

SCHEMBL24256967

CCCc1nc2sc3c(OCCc4ccc(OC)c(OC)c4)ncnc3c2c2c1CCC2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
POLB P06746 6/20 0.46
RXFP1 Q9HBX9 5/20 0.46
OPRK1 P41145 2/20 0.46
NPSR1 Q6W5P4 3/20 0.44
MAPK1 P28482 2/20 0.44
KMT2A Q03164 2/20 0.44
RAD52 P43351 1/20 0.44
MAPT P10636 3/20 0.42
HTT P42858 2/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
TSHR P16473 1/20 0.42
APOBEC3A P31941 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256356 0.85 NPC1 (0.48) ALDH1A1POLBRXFP1OPRK1NPSR1
SCHEMBL24256689 0.84 ALDH1A1 (0.48) ALDH1A1POLBRXFP1OPRK1NPSR1
SCHEMBL24256696 0.84 CHRM4 (0.48) ALDH1A1POLBRXFP1OPRK1NPSR1
SCHEMBL24256706 0.84 NPC1 (0.49) ALDH1A1POLBRXFP1OPRK1MAPK1
SCHEMBL24256969 0.83 KDM4E (0.46) ALDH1A1POLBRXFP1OPRK1NPSR1
SCHEMBL24256703 0.79 POLB (0.47) ALDH1A1POLBRXFP1OPRK1NPSR1
SCHEMBL24256615 0.75 KDM4E (0.44) ALDH1A1POLBRXFP1OPRK1NPSR1
SCHEMBL24256699 0.73 KDM4E (0.49) ALDH1A1POLBRXFP1OPRK1NPSR1
SCHEMBL26780366 0.73 POLB (0.78) ALDH1A1POLBRXFP1OPRK1NPSR1
SCHEMBL24256693 0.72 KDM4E (0.46) ALDH1A1POLBRXFP1OPRK1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 ALDH1A1 1934/4885POLB 2123/4885RXFP1 4473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.